Analyzing Real-World Data & Investigating Genotype-Phenotype Data to Support Precision Medicine Drug Development in Rare Disease
The recent onset of COVID-19 has advanced the demand for innovation as the pandemic illuminates the fractured and segmented nature of the healthcare system. Due to current social and health restrictions,
Precision Digital Health, Inc. (PDH) recognizes privacy as both a legal obligation and a critical element of customer service. PDH leverages real-world data from various patient data sources, such as electronic health records, device data (from both medical devices and wearables) and EDC trial data sourced from our Life Sciences partners…
Precision Digital Health, Inc. becomes a Hortonworks partner and achieves Hortonworks certification for their enterprise SUMMA™ platform (SaaS) that provides real-time analytics to surface insight using real-world data, wearables and medical devices. Our clients can design, execute and analyze data
Boston, MA, August 2018, Boston Millennia Partners is pleased to announce that the BMP Founders Fund has led a financing for Precision Digital Health (“PDH”). PDH has developed an enterprise software platform, Summa, that enables the integration of disparate clinical
Precision Digital Health has broadened its service offering by partnering with 23andMe to resell genotyping services for our clients interested in adding genomic and phonemic data sets to their research. 23andMe is currently the only genetic service direct to consumer
Precision Digital Health’s CEO and Cofounder, Thomas Wells, presented their SUMMA™ Real-World Evidence Interoperability Platform at the HL7® FHIR® Applications Roundtable at the Harvard Medical School in Boston. Our platform provides an end-to-end solution to enable researchers to ask and validate questions they never